Patent ID: 8999647
Filing Date: 2015-04-07
Classification: C12Q,G01N

Abstract:
1. A method of determining the aggressiveness of a ductal carcinoma in situ (DCIS) lesion of the breast comprising: (a) detecting the DNA copy number of CELSR1 in a sample from the DCIS lesion of the breast, wherein the DNA copy number is detected by array comparative genomic hybridization (aGCH), quantitative PCR, or in situ hybridization; (b) comparing the DNA copy number of CELSR1 in the sample against a normal DNA copy number of CELSR1, wherein the normal DNA copy number of CELSR1 is two; (c) determining the aggressiveness of the DCIS lesion based on the comparison in step (b), wherein an increased DNA copy number of CELSR1 is indicative of an indolent DCIS lesion.